TrialClinical pharmacology and therapeutics2026

Optimal Dose and Safety of Intravenous Favipiravir in Hospitalized Patients With COVID-19: A Dose-Escalating, Randomized Controlled Phase Ib Study.

Tim Rowland et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.